<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857011</url>
  </required_header>
  <id_info>
    <org_study_id>ISAPA UNIFESP 01</org_study_id>
    <nct_id>NCT01857011</nct_id>
  </id_info>
  <brief_title>Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty</brief_title>
  <acronym>ISAPA</acronym>
  <official_title>Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravenous or oral iron are effective in
      the treatment of postoperative anemia and iron deficiency in patients submitted in
      postbariatric abdominoplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter open randomized clinical trial with allocation ratio 1: 1. 56 adult patients
      undergoing post- bariatric abdominoplasty will be evaluated. The study group will receive 200
      mg of intravenous iron in the immediate postoperative period and a second application on day
      1 postoperatively. The control group will receive 100 mg of oral iron twice daily for 8
      weeks. Haematological variables , iron 's profile , quality of life ( SF -36 and FACT- An)
      and adverse events will be assessed preoperatively and on the first , fourth and eighth weeks
      postoperatively .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>8 postoperative weeks</time_frame>
    <description>Hemoglobin level measured at 8 postoperative weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ferritin levels</measure>
    <time_frame>Preoperative (one day before surgery) and 1, 4 and 8 postoperative weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACIT</measure>
    <time_frame>Preoperative (one day before surgery) and 1, 4 and 8 postoperative weeks</time_frame>
    <description>The FACIT Fatigue Scale is a health related quality of life (HRQOL) questionnaire targeted to evaluate fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36</measure>
    <time_frame>Preoperative (one day before surgery) and 1, 4 and 8 postoperative weeks</time_frame>
    <description>Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin saturation</measure>
    <time_frame>Preoperative (one day before surgery) and 1, 4 and 8 postoperative weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin levels</measure>
    <time_frame>preoperative (one day before surgery) and 1, 4 postoperative weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Anemia, Iron-Deficiency</condition>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>IV Iron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Iron sucrose</intervention_name>
    <description>Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.</description>
    <arm_group_label>IV Iron</arm_group_label>
    <other_name>Noripurum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Iron</intervention_name>
    <description>Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.</description>
    <arm_group_label>Oral Iron</arm_group_label>
    <other_name>Noripurum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women

          -  18 a 55 years

          -  Prior open or laparoscopic standard limb Roux and Y gastric bypass

          -  BMI &lt; 32 kg/m2

          -  Stability of weight loss for at least 6 months

          -  grade 3 abdominal deformity on the Pittsburgh scale

        Exclusion Criteria:

          -  Illiterate

          -  Current smoking

          -  Prior IV iron use in the last 3 months

          -  Uncontrolled systemic diseases

          -  Hemoglobin &lt; 11 g/dL

          -  Ferritin &lt;11 ng/mL

          -  Ferritin &gt; 100 ng/mL

          -  transferrin saturation &lt;16%

          -  transferrin saturation&gt; 50%

          -  B12 &lt; 210 pg/mL

          -  Folic Acid &lt; 3.3 ng/mL

          -  Albumin &lt; 2 g/dL

          -  C reactive protein&gt; 5 mg/L

          -  Prior Anaphylactic reaction to IV iron
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan-Carlos Montano-Pedroso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal University of São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Juan Carlos Montano Pedroso</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Anemia, Iron-Deficiency</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>abdominoplasty</keyword>
  <keyword>surgery, plastic</keyword>
  <keyword>iron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Teferrol</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

